Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974886 | 0.79 | MEN1 (0.39) | POLB | |
| SCHEMBL11476710 | 0.79 | ALDH1A1 (0.38) | TERTNOS3NOS1HIF1ARAD52 | |
| SCHEMBL8775918 | 0.78 | MGLL (0.43) | HIF1APOLB | |
| SCHEMBL4079827 | 0.76 | KEAP1 (0.32) | — | |
| SCHEMBL7609502 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL11758314 | 0.71 | — | — | |
| SCHEMBL4974074 | 0.70 | — | — | |
| SCHEMBL120097 | 0.69 | PIK3CD (0.47) | — | |
| SCHEMBL15330853 | 0.68 | INMT (0.34) | — | |
| SCHEMBL6852074 | 0.68 | PIK3CD (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073815-A1 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | University of Utah Research Foundation (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7425635-B2 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425635-B2 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425635-B2 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-09-16 | — | — | US | disclosed |
| WO-2006076337-A1 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20050267172-A1 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-01 | — | — | US | disclosed |
| US-6841536-B2 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1493736-A1 | Prodrugs and conjugates of selenol-containing compounds and methods of use thereof | University of Utah Research Foundation (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030225255-A1 | Use in reducing unwanted side effects of chemo- or radiotherapy of cancer, improving cardiovascular function, preventing mutagenesis, preventing initiation or progression of cancer, reducing toxic consequences of radiation exposure | NATIONAL INSTITUTES OF HEALTH--DIRECTOR DEITR | 2003-12-04 | — | — | US | disclosed |
| EP-1003760-A4 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | UNIV UTAH (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6340746-B1 | THIOLAMINE OR SELENOLAMINE CONJUGATE WITH ANTIOXIDANT VITAMIN; NONTOXIC | UNIVERSITY OF UTAH | 2002-01-22 | — | — | US | disclosed |
| EP-1003760-A1 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | THE UNIVERSITY OF UTAH (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007719-A1 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | UNIVERSITY OF UTAH (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225255-A1 | Use in reducing unwanted side effects of chemo- or radiotherapy of cancer, improving cardiovascular function, preventing mutagenesis, preventing initiation or progression of cancer, reducing toxic consequences of radiation exposure | SCLY, DOHH, GSTO1 | TERT 2181/4885NOS3 1182/4885NOS1 1150/4885 |
| US-20050267172-A1 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | SCLY, SELENOI, GSTO1 | TERT 656/4885NOS3 2512/4885NOS1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.